Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

67.24 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials
 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Bristol Myers Squibb Secures Canadian Regulatory Nod For Lung Cancer Candidate In Neoadjuvant Setting
Health Canada announced approval for Bristol Myers Squibb’s (NASDAQ: BMY) OPDIVO (nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks... 
Via Benzinga
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie. 
Via Investor's Business Daily
What Are Whales Doing With Bristol-Myers Squibb
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review
 
Via Benzinga
Bristol-Myers Squibb Expects Lower FY22 Sales Versus FY21
 
Via Benzinga
Michael Burry Puts His Money Where His Mouth Is For Market Crash Prediction: But Did He Sell Too Soon?
Famed “Big Short” investor Michael Burry has taken an extremely bearish stance during the third quarter of 2022 — but was it too much? 
Via Benzinga
NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition
NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for  
Via Benzinga
Blue Chip Stocks In Focus: Bristol-Myers Squibb
The company has grown earnings by more than 20% per year on average over the last five and ten years. This explosive growth has enabled the company to continue growing its dividend. 
Via Talk Markets
Why Michael Burry Is Betting Big on Just ONE Secretive Stock
Shares of GEO stock are in full focus after Michael Burry's Scion Asset Management reported the prison company as its only 13F holding. 
Via InvestorPlace
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
 
Via Benzinga
TC BioPharm Says It Aims To Deliver A Big Breakthrough In Cancer Treatments
Approximately 1.7 million new cancer cases are reported every year in the United States. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Looking At Bristol-Myers Squibb's Recent Whale Trades
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Analyzing Bristol-Myers Squibb's Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 29.89% since its last report. The company recently reported that it has 27.33 million shares sold short,... 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
The major indexes made big moves amid key earnings and another big Fed rate hike. 
Via Investor's Business Daily
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty. 
Via Benzinga
Bristol Myers Squibb Q2 Earnings And Revenues Surpass Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.93 per share. 
Via Talk Markets
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022
Bristol Myers Squibb continues to expect a $10 billion or double-digit decline from its generics-facing products. 
Via Investor's Business Daily
Recap: Bristol-Myers Squibb Q2 Earnings
  Bristol-Myers Squibb (NYSE:BMY) reported its Q2 earnings results on Wednesday, July 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
U.S. Stock Futures Gain; All Eyes On Fed Decision
Pre-open movers 
Via Benzinga
Boeing, Meta Platforms And 5 Stocks To Watch Heading Into Wednesday
With US stock futures trading higher this morning on Wednesday ahead of earnings reports from several big companies, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Tuesday's Market Minute: Tech Heavyweight Earnings On Deck: GOOGL, MSFT, META, AMZN, AAPL
U.S. equities wobbled to start arguably the busiest week of earnings of the quarter. Monday kicked off the final week of trading for the month of July, and despite initial overall weakness... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.